Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2020-07-20 Transaction in Own Shar…
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
Acquisition ou cession des actions de l'émetteur / Descriptif du programme de rachat
Transaction in Own Shares Classification · 98% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its subject is the "DESCRIPTIF DU PROGRAMME DE RACHAT D'ACTIONS" (Description of the Share Buyback Program). It details the authorization, objectives, and modalities of a share repurchase program, referencing the AMF (Autorité des Marchés Financiers) regulations and a resolution from the Annual General Meeting (AGM). A share repurchase program is a specific type of capital structure activity or transaction in own shares. Since the document explicitly describes the terms of the company buying back its own shares, the most precise classification is 'Transaction in Own Shares' (POS). It is not a general Earnings Release (ER) or a comprehensive Interim Report (IR).
2020-07-20 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and details significant corporate actions: a strategic equity investment (37.17% stake) in an American company (ProciseDx) and a distribution agreement. It announces financial transactions, strategic partnerships, and product pipeline updates. This type of announcement, detailing material corporate events outside of routine financial reporting (like 10-K or IR), is typically classified as a general corporate announcement or regulatory filing. Since it is a press release announcing strategic corporate activity (investment, partnership, distribution rights), it fits best under the general Regulatory Filings category (RNS) as it is not a specific financial report (10-K, IR, ER) or a specific corporate action like a dividend (DIV) or share repurchase (POS). The document also mentions the next scheduled publication (Chiffre d'affaires semestriel 2020) on July 21, 2020, confirming this document is an announcement, not the report itself. Given the nature of the announcement (strategic investment and partnership), RNS is the most appropriate general category.
2020-07-20 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces the deployment of COVID-19 rapid tests following a government decree. It details operational changes, sales figures, and provides contact information for investor relations and listing sponsors. Crucially, at the end, it states: "Prochaine publication : Chiffre d'Affaires semestriel 2020, le 21 juillet 2020, après Bourse." This structure—a news announcement about a business development, often including financial context or upcoming reporting dates, issued as a press release—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not the full financial report (like 10-K or IR) but an announcement regarding business operations and market reaction, and it is not explicitly a proxy statement (DEF 14A) or a management discussion (MDA), the most fitting category for a timely, material announcement that isn't a full financial statement is the Earnings Release (ER) category, as these press releases often accompany or precede formal earnings releases, or serve a similar function in communicating immediate material news. However, given the content is primarily about a regulatory change enabling product sales rather than reporting past financial results, it leans towards a general regulatory announcement. Since it is a formal press release announcing a significant operational/market event, and it is not a specific filing like 10-K or IR, it fits best under the general Regulatory Filings (RNS) category, which serves as a fallback for official, non-standardized announcements. Given the context of a press release announcing operational news, RNS is the most appropriate general classification.
2020-07-15 French
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated June 19, 2020, announcing the first day of trading for redeemable stock warrants (BSAR). It explicitly mentions that the attribution of these warrants is intended to 'give the Company the means to thank its existing shareholders... and to finance the acceleration of its development.' This action directly relates to changes in the company's capital structure and fundraising activities. Based on the definitions, 'Capital/Financing Update (Code: CAP)' is the most appropriate classification, as it covers company fundraising and capital structure changes. The document is an announcement, not a comprehensive report, but the subject matter is specific enough to warrant CAP over the general RPA or RNS.
2020-06-19 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document details the free attribution of redeemable stock warrants (BSAR) to all existing shareholders of Biosynex. It outlines the terms, exercise price, duration, and the potential capital increase resulting from the exercise of these warrants. This action directly relates to changes in the company's capital structure and the issuance of new securities (warrants leading to potential shares). This fits the definition of 'Capital/Financing Update' (CAP), as it is a specific financing/capital structure event being announced to shareholders, distinct from a general earnings report or a simple announcement of a report's publication. The document is comprehensive, not just a brief announcement, suggesting it is the primary disclosure for this specific corporate action.
2020-06-17 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is titled "Point sur l'activité à fin mai 2020" (Activity update as of end of May 2020) and reports key financial figures (CA de 34 M€ à fin mai) and confirms annual growth perspectives. It is explicitly labeled as a "COMMUNIQUÉ DE PRESSE" (Press Release). This format, focusing on key financial highlights for a specific period (May 2020, which is interim/quarterly related) but presented as a brief announcement rather than a comprehensive report (like a 10-K or IR), strongly aligns with the definition of an Earnings Release (ER). Furthermore, it announces the next publication date for the semi-annual results ("Chiffre d'Affaires semestriel 2020, le 21 juillet 2020"), confirming its role as a pre-report update. It is not a full report (10-K, IR), a transcript (CT), or a management discussion (MDA), but a summary release. FY 2020
2020-06-16 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.